Translate this page into:
The relationship between the use of fluconazole & the incidence of fluconazole-resistant Candida species
*For correspondence: ccm870958@yahoo.com.tw
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Sir,
We read with interest the study by Oberoi et al1 about epidemiology of non-albicans Candida species fungaemia in a tertiary care hospital. They showed an increasing incidence of non-albicans Candida species fungaemia as well as the increasing use of fluconazole. To understand the association about the consumptions of antifungal agents and the antifungal resistance among clinical isolates of Candida species is important, however, the impact of consumption of antifungal agents on the incidence of candidemia caused by different Candida species varies2. The authors of this study got an opportunity to clarify the relationship between the use of fluconazole and the incidence of fluconazole-resistant Candida species. By this analysis, their conclusion about limited use of azole as a presumptive therapy for Candida fungaemia in this clinical situation may become more reliable.
